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ORIGINAL ARTICLE
Activation of Kv7 channels with the anticonvulsant retigabine alleviates
neuropathic pain behaviour in the streptozotocin rat model of
diabetic neuropathy
Laiche Djouhria, Mohammed Imad Malkia, Asad Zeidana, Karim Nagia and Trevor Smithb
aDepartment of Basic Medical Sciences, College of Medicine, QU Health, Qatar University, Doha, Qatar; bDepartment of Medical Physics &
Biomedical Engineering, University College London, London, UK
ABSTRACT
Diabetic peripheral neuropathy (DPN) is the most incapacitating complication of diabetes mellitus. Up to
50% of patients with DPN develop peripheral neuropathic pain (PNP). The underlying ionic and molecular
mechanisms of diabetic PNP (DPNP) are poorly understood. However, voltage gated potassium (Kv7) chan-
nels which have been implicated in the pathogenesis of other types of PNP are likely to be involved. Here
we examined, in the streptozotocin (STZ) rat model of DPNP, whether activating the Kv7 channels with a
potent activator retigabine (ezogabine) would reverse/attenuate behavioural signs of DPNP. STZ rats
exhibited behavioural indices of mechanical and heat hypersensitivity, but not cold hypersensitivity or
spontaneous pain, 35days after STZ injection. Retigabine given at a dose of 15mg/kg (but not at 7.5mg/
kg, i.p.) significantly attenuated mechanical, but not heat hypersensitivity in DPNP rats, and was as effect-
ive as the positive control gabapentin. This analgesic effect of retigabine was completely reversed by the
Kv7/M channel blocker XE991 (3mg/kg, i.p.) indicating that the anti-allodynic effects of retigabine were
mediated by Kv7 channels. In conclusion, the findings suggest that Kv7 channels are involved in DPNP
pathogenesis, and that strategies that target their activation may prove to be effective in treating DPNP.
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This study demonstrates that streptozotocin (STZ) rats exhibit,
5weeks after STZ injection, behavioural signs of mechanical and
heat hypersensitivity, but not cold hypersensitivity or spontaneous
pain. The study also shows that activation of Kv7 channels with
retigabine dose dependently attenuated STZ-induced mechanical,
but not heat hypersensitivity. The findings that these anti-allo-
dynic effects of retigabine were reversed by the Kv7/M channel
blocker XE991 indicate that they were mediated by Kv7 channels.
The findings suggest that strategies that target activation of Kv7
channels may be effective in treating diabetic peripheral neuro-
pathic pain.
Introduction
Peripheral neuropathic pain (PNP), pain arising as a direct conse-
quence of a lesion or disease affecting the peripheral nervous sys-
tem, is associated with many types of injury/disease, including
diabetes mellitus. Diabetic peripheral neuropathy (DPN) is the
most persistent and incapacitating complication of both type 1
and type 2 diabetes mellitus [1], and is the most common cause
of PNP, with 34–50% of people with DPN having some degree of
PNP [1–3]. Patients suffering from DPN can experience a large
spectrum of sensory symptoms that are often concurrent with loss
of sensation in the extremities which frequently leads to foot
ulcers that may progress to limb amputations [4,5]. PNP induced
by diabetes (DPNP) is characterised by unpleasant positive
symptoms including spontaneous pain, mechanical hypersensitiv-
ity/allodynia (painful sensation caused by light touch), paresthesias
(tingling), as well as negative symptoms notably heat hypoalge-
sia [6].
Despite its high prevalence and clinical importance, successful
therapy for DPNP remains a challenge because the use of cur-
rently available drugs is limited by marginal efficacy and signifi-
cant adverse side effects. Several mechanisms have been
proposed for the pathogenesis of PNP including increased excit-
ability of nociceptive dorsal root ganglion (DRG) and CNS neurons
[7]. There is accumulating experimental evidence to support
involvement of some of these mechanisms in DPNP pathogenesis
[1]. Indeed preclinical studies suggest that, like other types of
PNP, DPNP is due at least partly to abnormal hyperexcitability of
DRG neurons [8,9]. This is based on the findings of studies using
rodent models of DPNP showing that both C- and A-fibre DRG
neurons exhibit aberrant spontaneous activity, the key characteris-
tic of neuronal hyperexcitability [10–13].
The underlying ionic and molecular mechanisms of the aber-
rant hyperexcitability of DRG neurons associated with DPNP are
not fully understood, but changes in expression and/or activation
properties of voltage-gated Kv7 potassium channels, which pro-
duce an outward current (known as IM) that normally exerts a
powerful stabilising influence on neuronal excitability [14,15], are
likely to be involved. This is because acute inhibition of Kv7 chan-
nels with a specific blocker XE991 increases excitability of DRG
neurons [16,17], enhances Ad-fibre discharges induced by mech-
anical or thermal stimuli [18] and causes nocifensive behaviour in
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rats [19,20]. Conversely, activators of Kv7 channels, such as retiga-
bine and flupiritine, have been shown to block spontaneous activ-
ity in axotomised sensory fibres [21], attenuate C- and Ad-fibre
discharges induced by heat stimuli [18], reduce excitability of C-
fibres in human sural nerves [22] and have an analgesic action in
animal models of pain including surgically induced PNP [23]. In
the present study, we examined whether activating Kv7 channels
with retigabine would also attenuate pain hypersensitivity in the
streptozotocin rat model of DPNP. Our results show that retiga-
bine dose dependently attenuated mechanical, but not heat
hypersensitivity in DPNP rats.
Materials and methods
Experimental animals
In the present study, 64 male Sprague Dawley rats (250–300 g)
were used; they were housed four rats per cage in a room in the
animal house of Liverpool University, UK. The room was main-
tained at room temperature between 21 and 24 C under standard
laboratory conditions with 12-h light/dark cycles and free access
to food and water. The experimental protocols were approved by
the University of Liverpool Ethical review committee, and com-
plied throughout with the UK Animals (Scientific Procedures)
Act 1986.
The animal model of diabetic peripheral neuropathic
pain (DPNP)
A number of well-characterised animal models of DPNP have
been developed to investigate its pathophysiology including the
widely used STZ (streptozotocin) rat model. STZ (an alkylating che-
motherapeutic agent that is used in the treatment of pancreatic b
cell carcinoma) is the most prominent diabetogenic chemical
agent in diabetes research. It causes hypoinsulinemia and hyper-
glycaemia as a result of its cytotoxicity to pancreatic b cells. The
STZ model (model of type 1 diabetes) is more commonly used
than other models of DPNP because of its low cost, rapid induc-
tion, greater stability and relative lack of toxicity to other organs
[1,24,25]. Therefore we used this model which involves a single
injection of STZ (60mg/kg, i.p.) after an overnight fast to reduce
competition between glucose and STZ for uptake into pancreatic
b-cells. Experimental rats were observed daily.
Pain behavioural testing
Pain behavioural testing was conducted on 64 rats by an experi-
menter who was blind to the various treatment groups of the ani-
mals. As we have reported previously [26–28], testing was
performed in plastic chambers after the rats were acclimatised for
3 consecutive days to the procedure room, the testing chambers
and the devices used (see below). On the testing days, the rats
were also habituated to the chambers by placing each rat in the
plastic chamber for at least 15min before testing. After the rats
had habituated to the chambers (after the exploratory and
grooming behaviour had ceased), paw withdrawal threshold
(PWT), paw withdrawal latency (PWL), cold escape/nocifensive
behaviour, and spontaneous foot lifting (SFL), if any, were
assessed on the left hind paw of each control/vehicle and experi-
mental rat (see below).
Behavioural testing for mechanical hypersensitivity (allodynia)
Behavioural testing for mechanical hypersensitivity/allodynia was
performed using an automated von Frey type system known as a
dynamic plantar aesthesiometer touch stimulator (Ugo Basile,
Italy) as described previously [28]. Briefly, rats were placed in plex-
iglass boxes (15 15 20 cm) on a wire mesh, and the mid-
plantar surface of the left hind paw of each rat was stimulated
with a blunt metal probe (0.5mm in diameter) three times with a
minimum of 5-min interval between each trial. An abrupt with-
drawal lifting or flicking of the hind paw in response to the pres-
sure (mechanical force) applied with the metal probe was defined
as a positive response. The average force of the three trials (in
grams) that resulted in paw withdrawal was calculated and
considered as PWT. To determine the baseline values, the test was
conducted one day before STZ injection on experimental rats.
The test was repeated 35 d post STZ to determine whether
the rats developed mechanical hypersensitivity. As reported previ-
ously [27–29] mechanical hypersensitivity was indicated by a sig-
nificant decrease in the mean PWT. To determine effects of drugs
on mechanical hypersensitivity, the test was also conducted at
different time points after treatment with various drugs or
their vehicles.
Behavioural testing for heat hypersensitivity (heat hyperalgesia)
Behavioural testing for heat hypersensitivity/hyperalgesia was per-
formed using Hargreaves analgesiometer (Ugo Basile, Comerio,
Italy) as described previously [27–29]. Heat hypersensitivity was
indicated by a significant decrease in the mean paw withdrawal
latency (PWL) to a noxious heat stimulus applied to the mid-
plantar surface of the hind paw (L4 dermatome) of each rat. The
procedure of this test is similar to that used for mechanical hyper-
sensitivity (see above) except that, in this test, the rats were
placed on a 2-mm-thick glass floor under which the laser radiant
heat source was positioned. The onset of the heat stimulus, acti-
vated a timer that stopped automatically when paw withdrawal
was detected by a photocell of the analgesiometer. The average
response latency (in seconds) of three trials was calculated and
considered as PWL.
Behavioural testing for cold hypersensitivity
Behavioural testing for cold hypersensitivity was performed using
the hot/cold plate analgesiometer (Ugo Basile, Milan, Italy) which
can be cooled to 3 C (at an ambient temperature between 20
and 25 C). Before conducting the cold sensitivity test, rats were
allowed to acclimate to the testing apparatus for 1 h, then the
test was conducted by placing each rat on a metal surface of the
cold plate maintained at 5 C within a transparent plexiglass
chamber (16 16 27 cm). As described previously by various
investigators [28,30], the duration (in seconds) of the escape/noci-
fensive behaviour (licking, lifting, guarding, shaking or biting of
the hind paw or jumping) per a 2min period was measured, using
a stop watch, in control (vehicle treated) and STZ-treated rats. To
determine the baseline values of cold sensitivity, rats were tested
one day before STZ injection. The average of two separate trials
with at least 2 h separating each trial was used. The cold sensitiv-
ity test did not result in any signs of tissue injury.
Behavioural testing for spontaneous pain
Spontaneous foot lifting (SFL) duration has been used by numer-
ous previous studies as a measure of spontaneous/ongoing pain
in various animal models of pain (see [26,31] and references
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therein). Therefore, in this study, we examined whether STZ
treated rats exhibit this spontaneous pain behaviour. This test was
performed by placing each rat in one of the plexiglass boxes
(n¼ 3) used for the Hargreaves test and observing SFL (spontan-
eous lifting of the left hind foot off the glass floor) as described
previously [26,31]. Any foot lifting associated with locomotion,
body repositioning, or grooming was excluded [26]. This test was
conducted only 35 d post-STZ because normal (untreated) rats do
not exhibit SFL.
Animal groups and drug administration
A total of 64 rats were used in the present study. Of these, 52 rats
received a single injection of a STZ (60mg/kg, i.p.). The remaining
12 rats were naïve rats (not injected with STZ) and were used for
examining the effects of the Kv7 agonist retigabine (n¼ 6 rats)
and antagonist EX991 (n¼ 6 rats) on baseline pain sensitivity. The
STZ rats (n¼ 52) were divided randomly into five groups: (1)
group 1 (retigabine group A, n¼ 10 rats); each rat in this group
received a single dose of 15mg/kg retigabine; (2) group 2 (retiga-
bine group B, n¼ 10 rats); each rat in this group received a single
dose of 7.5mg/kg retigabine; (3) group 3 (vehicle control group
for groups 1 and 2, n¼ 10 rats); (4) group 4 (EX991þ retigabine
group, n¼ 10 rats) received a single dose of the Kv7 antagonist
EX991 (3mg/kg) plus a single dose of 15mg/kg retigabine and (5)
group 5 (gabapentin, positive control group, n¼ 12). All the drugs
and their vehicles were administered intraperitoneally. None of
the STZ-treated rats showed any gross neurological abnormalities
or any sign of self-mutilating behaviour or autotomy.
Retigabine (N-(-2-amino-4-(4-fluorobenzylamino)-phenyl) car-
bamic acid ethyl ester), the kv7 channels opener kindly donated
by Dr Blackburn-Munro (NeuroSearch, Ballerup, Denmark), XE-991
(10,10-bis(4-pyridinylmethyl)-9(10H)-antracenone), the kv7 channel
blocker and STZ (Sigma-Aldrich, St. Louis, MO) were dissolved in
dimethyl sulphoxide (DMSO)and stored in aliquots at 20 C. All
compounds were diluted in sterile physiological saline immedi-
ately prior to their use to prevent degradation of the compound.
Rats (n¼ 52) were randomised to five groups (see Results). The
five group of rats were injected with these drugs or vehicle (at
volume of 1ml/kg) 35 d after STZ injection i.e. after the behav-
ioural signs DPNP were fully established. The behavioural tests
were performed before (pre-drug) drug treatment (35 d after STZ
treatment) and 1–2 h, 2–3 h and 24 h after drug or vehicle (DMSO
in physiological saline) treatment.
Statistics analysis
The data were found to be normality distributed (Shapiro–Wilk
normality test) and are, therefore, presented as the mean± SEM
(and statistical analysis was made with t-test). One-way repeated-
measures analysis of variance (ANOVA) with post hoc tests was
used for comparisons between pre-drug and post-drug values at
different time points. All of the statistical tests were performed
using Graphpad Prism 5 (Graphpad Software, San Diego, CA). p
Values of less than .05 were considered significant (statistical sig-
nificance: p< .05; p< .01; p< .001).
Results
Validation of the diabetogenic action of STZ in rats
As shown in Figure 1, prior to injection of STZ, there was no signifi-
cant difference in the blood glucose concentrations between the rats
designated as the control group (n¼ 12) and those designated as
the experimental (STZ) group (n¼ 18). However, as shown in Figure
1(A), STZ rats exhibited significantly (p< .001, unpaired t-test)
increased blood glucose concentrations 3d post-STZ compared with
the control group. STZ-treated rats remained hyperglycaemic there-
after. Indeed, as shown in Figure 1(A), the blood glucose of the STZ
group remained significantly higher (p< .001, unpaired t-test) than
that of controls 35d post-STZ. Rats (n¼ 5) that did not exhibit hyper-
glycaemia after STZ injection were excluded from analysis.
We also examined whether there is a difference in body weight
between hyperglycaemic (STZ) and control rats. We found that the
STZ group had significantly lower body weights than controls
throughout the study duration (Figure 1(B)). Indeed STZ rats weighed
significantly less than control rats at each of the time points tested
(1–5weeks) post-STZ (Figure 1(B)). The difference in the mean body
weight between STZ and control rats was more pronounced and
more significant (p< .0001) 5 weeks post-STZ. Indeed, at this time
point (5weeks post-STZ), the mean weight of STZ rats (208.5±5.4)
was 1.6 times less than that (324.0±9.5) of untreated (control) rats.
STZ rats exhibit behavioural indices of mechanical and heat,
but not cold, hypersensitivity or spontaneous pain
Having established that the STZ rats displayed chronic hypergly-
caemia, we sought to determine whether they exhibit behavioural
















































Figure 1. Hyperglycaemia and impairment of body weight gain in STZ rats. A
single injection of STZ (60mg/kg, i.p.) into rats caused a significant elevation in
blood glucose as early as 3 days post-injection (p< .001) compared to pre-STZ
baseline (control values) (A). STZ-treated rats remained hyperglycaemic thereafter
as indicated by an even greater increase in blood glucose concentration as 35 d
post-injection (A). This hyperglycaemia was accompanied by a gradual impair-
ment in body weight gain from 1 to 5weeks post-STZ (B). The mean body
weight of STZ rats was compared with that of control rats at each time point
using unpaired t-test. The level of significance is indicated with asterisks as fol-
lows: p< .001; p< .01 and p< .05.
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signs of PNP. Pain behaviours were assessed at 3 time points
(21, 31 and 35 d after STZ treatment), and the values of pain
behaviours at these time points were compared with the baseline
(pre-STZ) values (Figure 2). These time points were based on pilot
time-course experiments which showed mechanical hypersensitiv-
ity to be more significant at 35 d than at 31 d post-STZ, but not
significant at 21 d. As shown in Figure 2(A), there was a significant
decrease in the mean PWT at 31 (p< .05) and 35 (p< .001) days
post-STZ (but not at 21 d) indicating that STZ-treated rats devel-
oped behavioural signs of mechanical hypersensitivity at later
points than 3weeks of STZ treatment. However, STZ rats devel-
oped heat hypersensitivity/hyperalgesia at all the time points
tested (21, 31 and 35 d) as indicated by a highly significant
decrease (p< .001) in the mean PWL at those time points (Figure
2(B)). In contrast, there was a slight but insignificant increase in
the cold evoked responses at 35 d post-STZ (Figure 2(C)) indicat-
ing that STZ rats failed to develop cold hypersensitivity.
As noted in the Methods, numerous previous studies have
used spontaneous foot lifting (SFL) as a measure of spontaneous/
ongoing pain in various animal models of pain (see Djouhri et al.,
2006, 2012 and references therein). Therefore, we sought to deter-
mine whether STZ-treated rats exhibit SFL. We found that unlike
other models of PNP such as spinal nerve injury model [26,31]
and chemotherapy-induced PNP [28] which show significant SFL,
none of the STZ rats showed SFL indicating the STZ model does
not exhibit spontaneous pain behaviour.
Retigabine attenuates STZ-induced behavioural signs of
mechanical but not heat hypersensitivity
In the present study (which was conducted few years ago), we
examined in STZ rats, whether pharmacological activation of Kv7
channels with retigabine could reverse or attenuate mechanical
and heat hypersensitivity. As shown in Figure 3, a single injection
of retigabine at a dose of 15mg/kg, but not at 7.5mg/kg, given
35 d after STZ treatment, resulted in a significant increase in the
mean PWT at all time points tested (0–1 h, 1–2 h and 2–3 h post-
drug) indicating that retigabine injection caused attenuation of
the behavioural manifestations of mechanical hypersensitivity
induced by STZ treatment. However, the increase in PWL caused
by retigabine was statistically not significant at all of the time
points tested (Figure 3(B)) indicating that retiagbine does not
reverse/reduced heat hypersensitivity in STZ rats.
Blockade of Kv7 channels with XE991 reverses the analgesic
effects of retigabine
To confirm that the analgesic effects of retigabine are mediated
by activation of Kv7 channels, we used the Kv7 channel blocker
XE991 to examine whether the effects of retigabine on STZ-
induced mechanical and heat hypersensitivity could be reversed.
As shown in Figure 4, the effects of retigabine (15mg/kg) on PWT
(Figure 4(A)) was antagonised by XE991 (3mg/kg), compared with
the vehicle, indicating that the effects of retigabine on mechanical
hypersensitivity in the STZ rats can be reversed by this blocker.
Interestingly, the antiallodynic effects of retigabine were similar to
those of the positive control gabapentin (Figure 4(A)). As a con-
trol, we also tested both retigabine and XE991 for effect on PWT
and PWL in naïve (normal) rats. The result showed that neither
retigabine nor XE991 had any effect on the baseline PWT or PWL,
compared with the vehicle group (Figure 5(A,B)) indicating that
the effects of these drugs were mediated by Kv7 channels.
Discussion
The present study was aimed at investigating whether retigabine,
a potent non-selective activator of neuronal Kv7 channels that has
been approved for its use as an antiepileptic in humans, attenu-
ates pain hypersensitivity in the STZ rat model of DPNP. The find-











































































Figure 2. Behavioural indices of mechanical and heat hypersensitivity in STZ rats.
The data presented in this figure and Figures 2–5 are presented as mean± SEM.
STZ treatment significantly decreased the mean PWT (A) and the mean PWL (B)
at different time points after STZ treatment. The decrease in PWL was highly sig-
nificant (p< .001) at all three time points tested (21, 31 and 35 d post-treatment)
indicating development of heat hypersensitivity at these time points (B), whereas
the decrease in the PWT was significant at 31 (p< .05) and 35 (p< .001) days,
but not at 21 d post-STZ (A) indicting a delay in the development of mechanical
hypersensitivity. There was no significant change in the mean duration of cold
evoked responses (C) indicating that STZ rats do not exhibit cold hypersensitivity.
Note that for each behavioural type, comparisons were between values before
STZ treatment (pre-STZ, open bars) and 21 (light grey bars), 31 (dark grey bars)
and 35 (black bars) days post-STZ. Statistical tests were made with one-way
ANOVA with Tukey’s multiple comparison test. For the level of significance, see
legend to Figure 1.
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exhibited behavioural indices of mechanical and heat hypersensi-
tivity, but not cold hypersensitivity or spontaneous/ongoing pain,
(b) retigabine dose-dependently attenuated mechanical, but not
heat hypersensitivity in STZ-diabetic rats, (c) the effects of retiga-
bine were similar to those of the positive control gabapentin and
(d) the anti-allodynic effects of retigabine were completely
reversed by the Kv7/M channel blocker XE991 indicating that the
effects of retigabine are mediated by Kv7 channels, and that these
channels are involved in the pathogenesis of DPNP.
In the present study, we used the STZ model which has been
shown by numerous preclinical studies to exhibit long-lasting
behavioural signs of DPNP including mechanical and heat hyper-
sensitivity [32–42]. Consistent with these studies, we found that
STZ-diabetic rats developed significant behavioural signs of mech-
anical hypersensitivity (allodynia) 35d post-STZ. This behaviour is
believed to correspond to the cutaneous hypersensitivity in
patients that leads to acute distress on contact with an external
stimulus, such as clothing. Indeed, such mechanical hypersensitivity
can be so painful in some patients preventing them from perform-
ing their daily activities (thereby impacting their employment and
social life) and may lead to depression [43]. The anti-allodynic
effects of retigabine observed in the present study are unlikely to
be due to motor impairment because administration of retigabine
(10mg/kg) causes only a transient (15min) impairment of motor
performance in rats [44].
Although heat hypersensitivity (hyperalgesia) is infrequent in
patients with PDN [7], animal studies using rodent models of dia-
betes including the present study and the aforementioned studies
show that heat hypersensitivity develops within weeks of onset of
diabetes in most models of type 1 and type 2 diabetes. This
pain behaviour has been shown to persist in animals that retain
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Figure 4. Effects of retigabine, XE991 and gabapentin on mechanical and heat
hypersensitivity induced by STZ. STZ treatment significantly decreased mean paw
withdrawal threshold (PWT) to a mechanical stimulus (A) and mean paw with-
drawal latency (PWL) to a noxious heat stimulus (B) 35 d post-treatment in all
four groups of rats (vehicle, retiagbine, retigabine plus XE991 and gabapentin)
indicating that all rat groups developed mechanical (A) and heat (B) hypersensi-
tivity. Compared with vehicle (n¼ 10 rats), intraperitoneal injections of retigabine
(15mg/kg, n¼ 10) and gabapentin (10mg/kg, n¼ 12) significantly reduced
mechanical hypersensitivity at 2–3 h post-drug treatment (B). However, gabapen-
tin but not retigabine was also effective in alleviating heat hypersensitivity at
1–2 h post-drug. The effects of retigabine on mechanical hypersensitivity (A) was
blocked by injection of retigabine with the Kv7 channel antagonist XE991
(n¼ 10) indicating that the retigabine effects were mediated by Kv7 channels.
For statistical tests, see legend to Figure 3.
(B)
(A) Mechanical Hypersensitivity








































20 Ret 15 mg/kg7.5 mg/kg





















Figure 3. Effects of activating Kv7 channels with retigabine on mechanical and
heat hypersensitivity in STZ rats. A single injection of retigabine at a dose of
15mg/kg (grey bars), but not 7.5mg/kg (open bars), significantly reversed the
STZ-induced decrease in the mean PWT at all three time points tested (A) indicat-
ing that retigabine attenuated mechanical hypersensitivity induced by STZ.
However, retigabine given at both doses had no significant effect on heat hyper-
sensitivity induce by STZ (B). Comparisons were between the values at different
time points after retigabine (post-Ret) and those at 35 d after STZ but just before
retigabine injection (pre-Ret). Statistical tests were made with one-way ANOVA
and Tukey’s multiple comparison test. For the level of significance, see legend to
Figure 1.
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residual endogenous insulin production or are supplemented by
exogenous insulin [45]. However, heat hypersensitivity may pro-
gress to heat hypoalgesia/hyposensitivity in more insulinopenic
animals [45]. Indeed, Fox et al. (1999) reported that STZ rats exhib-
ited transient heat hyposensitivity lasting for about 4weeks post-
STZ. A recent study by McNaughton and his co-workers [46] has
also shown that STZ-treated mice develop heat hyposensitivity
6–8weeks post-STZ treatment. Heat hyposensitivity may be due
to sensory dysfunction and/or depletion of sensory nerve termi-
nals in the epidermis of patients as a result of diminished trophic
support by insulin [47,48]. Regardless of the mechanism of heat
hyposensitivity, it should be noted that the present and the afore-
mentioned studies that used the STZ model have not reported
heat hyposensitivity. The discrepancy between the studies may be
due to differences in the animal strain and/or the time point at
which the heat testing was conducted. However, development of
heat hyposensitivity in animal models of DPNP is not surprising
given that chronic hyperglycaemia is known to cause neuronal
degeneration and subsequent impairment of thermal perception
in human diabetic patients [49]. It is believed that the dual mani-
festation of mechanical hypersensitivity and heat hyposensitivity
mirrors the clinical presentation of PDN in humans [46].
Our findings that STZ-diabetic rats did not show significant
cold hypersensitivity are not in line with those of Courteix et al.
(1993), who reported that over 70% of their STZ rats exhibited
cold hypersensitivity. The reason for this apparent discrepancy is
not clear, but it might be due to differences in rat strains, dose of
the STZ and/or different methodologies used to assess cold
hypersensitivity. Indeed, Courteix et al. (1993) used a tail immer-
sion test to measure cold-evoked pain, as opposed to the cold
plate used in the present study. Those co-workers also used a
higher dose (75mg/kg, i.p.) of STZ than the dose (60mg/kg, i.p.)
used in the present study. These factors may also account for the
variability in the onset of DPNP behaviours between the different
animal studies.
One of the interesting findings of the present study is that,
STZ rats did not show any SFL, a behavioural index of spontan-
eous pain (see Djouhri et al., 2006, 2016 and references therein),
in agreement with those of Biessels et al. (2014) [50] who reported
that diabetic rodents do not show spontaneous pain behaviours
such as limb guarding, audible or ultrasonic vocalizations, or
autotomy. Taken together, these findings suggest that the STZ
model differs from other models of chronic pain which we and
others have previously shown to exhibit significant SFL including
models of inflammatory pain [26] and PNP induced by traumatic
nerve injury [26,27,31] or chemotherapy [28]. Unfortunately, how-
ever, none of the aforementioned animal studies reported
whether or not STZ rats show spontaneous pain behaviour.
It is noteworthy that the validity of STZ-treated animals as a
model of DPNP has been challenged by a number of investigators
[34,37,39] who suggested that the apparent PNP behaviour seen
in the STZ animals is independent of hyperglycaemia, and that it
is due to the antineoplastic effects of STZ. This proposal is based
on their findings that all STZ-treated rats, whether diabetic or not,
displayed mechanical hypersensitivity. In contrast, there is sub-
stantial evidence arguing against the suggestion that STZ toxicity
is directly responsible for the neuropathy phenotype including
that: (a) reversing hyperglycaemia by intensive insulin therapy
was found to alleviate pain hypersensitivity in STZ-diabetic rats
[32] and (b) animals treated concurrently with both STZ and O-
methyl-glucose, an agent that blocks the effects of STZ on the
pancreas, show no evidence of neuropathy [51]. It should be
pointed out that, in the present study, only diabetic STZ rats
were assessed for DPNP behaviours. It is also worth mentioning
that it was beyond the remit of the present study to determine
whether the non-diabetic STZ rats develop pain behaviours.
Numerous previous studies have shown that activating Kv7
channels with retigabine is effective in attenuating pain behav-
iours in various experimental models of pain. Indeed, retigabine
has been shown to display analgesic efficacy in multiple animal
pain models including models of temporomandibular joint pain
[52], visceral pain [53], inflammatory and nerve injury-induced
PNP [16,44,54,55], spinal cord injury [56]; trigeminal neuropathy
[57], bone cancer pain [58] and chemotherapy-induced PNP [59].
However, as far as we know, there has been only one study
showing that retigabine attenuated both mechanical and heat
hypersensitivity in STZ rats [60]. Our findings that retigabine
reduced mechanical hypersensitivity in STZ-diabetic are in line
with these findings. In contrast, however, our results show that
retigabine given at higher doses (15mg/kg and 7.5mg/kg) than
that (5mg/kg) used by these investigators [60] had no effect on
heat hypersensitivity in STZ-diabetic rats. The reason for this
apparent discrepancy might be due to a difference in the rat
strain (Sprague Dawley in the present study versus Wistar in their
study). However, since separate nociceptor subsets mediate
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Figure 5. Effects of retigabine and XE991 on pain sensitivity in naïve rats.
Compared to vehicle (n¼ 10), injections of an intraperitoneal dose of XE991
(3mg/kg/n¼ 6) or retigabine (15mg/kg, n¼ 6) into naive rats had no obvious
effects on pain sensitivity on normal rats as indicated by no significant changes
in the mean PWT (A) or PWL (B). Statistical tests were made with two-way
repeated measures ANOVA, with Bonferroni post-hoc test.
JOURNAL OF DRUG TARGETING 1123
mechanical and heat hypersensitivity, it is possible that the differ-
ent effects of retigabine on mechanical and heat hypersensitivity
are due to differential effects of the Kv7 channel activator on dif-
ferent nociceptor subpopulations (see [27] for discussion).
As noted in the Introduction, DPNP is likely to be due to
increased excitability of both DRG and CNS neurons both of which
express Kv7.2–7.5 voltage-gated Kþ channels that encode the M-
current [16]. Although it is difficult to ascertain precisely the mode
and site of retigabine action, it is possible that the anti-allodynic
effects of retigabine are mediated by Kv7 channels in large mye-
linated A-fibre neurons. This is because (a) STZ-induced mechan-
ical allodynia in mice was reversed by blockade of myelinated Ab-
afferent fibres [40], and (b) capsaicin-sensitive C-fibre nociceptors
are not required for the development of STZ-induced mechanical
allodynia in both rats [13] and mice [40]. It should be noted that
large myelinated A-afferent fibres, in particular Ab-fibre, have also
been implicated in mechanical allodynia seen in other models of
PNP [10,61,62]. This is based on the findings of these and other
studies [6,63–65] that blockade or ablation of unmyelinated C-
fibre nociceptors has limited effects on mechanical allodynia.
These findings suggest that nerve injury-induced mechanical and
heat hypersensitivities are mediated by separate nociceptor sub-
sets [66,67]. Thus, it is possible that differential effects of retiga-
bine on mechanical and heat hypersensitivity observed in the
present study are due to different effects of the Kv7 channel
opener on nociceptor subpopulations.
Conclusion
The present study provides direct evidence that, unlike other mod-
els of PNP, STZ-diabetic rats do not exhibit behavioural indices of
cold allodynia or spontaneous pain, and that the analgesic effects
of retigabine were similar to those of gabapentin. Our findings that
the anti-allodynic effects of retigabine were completely reversed
by the Kv7/M channel blocker XE991 implicate Kv7 in the DPNP
pathogenesis. These findings suggest that strategies that target
activation of Kv7 channels may be effective in treating DPNP.
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